The fifth Myeloma Meeting was held in San Diego, CA, and took place on 7–9 September, 2018. The Myeloma Meeting provides an opportunity for research leaders in the field of myeloma to discuss clinical advances in myeloma, in order to further our understanding of recent advances in myeloma, and to encourage interactive discussion. A key focus is the clinical management of myeloma.
Highlights from this year’s Myeloma Meeting include defining the genomics of myeloma in the development of novel targets, immune-based therapies such as CAR T-cell therapy, and utilizing measurable residual disease (MRD) as a prognostic indicator.
The Myeloma2018 Workshop was supported by: Celgene, Janssen, BMS, Amgen and Takeda